Home › Compare › BRIBF vs EQR

BRIBF vs EQR: Dividend Comparison 2026

BRIBF yields 1062.70% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRIBF wins by $32084463.96M in total portfolio value
10 years
BRIBF
BRIBF
● Live price
1062.70%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32084464.00M
Annual income
$27,073,008,093,454.87
Full BRIBF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — BRIBF vs EQR

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRIBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRIBF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
BRIBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF
Annual income on $10K today (after 15% tax)
$90,329.44/yr
After 10yr DRIP, annual income (after tax)
$23,012,056,879,436.64/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, BRIBF beats the other by $23,012,056,876,189.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + EQR for your $10,000?

BRIBF: 50%EQR: 50%
100% EQR50/50100% BRIBF
Portfolio after 10yr
$16042232.02M
Annual income
$13,536,504,048,637.23/yr
Blended yield
84.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BRIBF
No analyst data
Altman Z
19.2
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys
0
EQR buys
0
No recent congressional trades found for BRIBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRIBFEQR
Forward yield1062.70% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$32084464.00M ✓$40.5K
Annual income after 10y$27,073,008,093,454.87 ✓$3,819.61
Total dividends collected$31704729.30M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BRIBF vs EQR ($10,000, DRIP)

YearBRIBF PortfolioBRIBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$116,970$106,269.93$11,248$547.57+$105.7K → BRIBF
2$1,286,876$1,161,718.25$12,701$666.53+$1.27M → BRIBF
3$13,321,776$11,944,818.28$14,405$814.59+$13.31M → BRIBF
4$129,817,926$115,563,625.92$16,413$999.84+$129.80M → BRIBF
5$1,191,375,681$1,052,470,500.56$18,795$1,232.92+$1191.36M → BRIBF
6$10,301,704,979$9,026,933,000.21$21,639$1,527.95+$10301.68M → BRIBF
7$83,971,400,363$72,948,576,035.34$25,057$1,903.80+$83971.38M → BRIBF
8$645,568,504,677$555,719,106,288.88$29,197$2,385.87+$645568.48M → BRIBF
9$4,683,603,649,023$3,992,845,349,018.69$34,250$3,008.70+$4683603.61M → BRIBF
10$32,084,463,997,910$27,073,008,093,454.87$40,467$3,819.61+$32084463.96M → BRIBF

BRIBF vs EQR: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BRIBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHDBRIBF vs JEPIBRIBF vs OBRIBF vs KOBRIBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.